Create a free Feed Strategy account to continue reading

FDA pauses facility inspections as COVID cases spread

FDA implemented temporary changes to its inspectional activities as a result of the spread of the omicron variant of COVID-19.

Foreman Builder, Engineer Or Inspector In Green Safety Vest Refl
giggsy25 | Bigstock.com

The U.S. Food and Drug Administration (FDA) has paused facility inspections as a result of the spread of the omicron variant of COVID-19.

FDA implemented temporary changes to its inspectional activities on December 29 “to ensure the safety of its employees and those of the firms it regulates,” it said. The agency will continue “mission-critical” work through January 19 but has temporarily postponed certain inspectional activities with the hopes of restarting these activities as soon as possible.

“The FDA will continue conducting mission-critical foreign inspections and will reassess plans as needed based on its monitoring foreign travel conditions,” FDA said in an update on its website. “The agency also is postponing the planning of prioritized surveillance foreign inspection assignments that were scheduled to begin in February 2022. The FDA is also continuing to conduct mission-critical domestic inspections. State inspections under FDA contract have the discretion to make inspection decisions based on their local information.”